Welcome to ActoGeniX

ActoGeniX is a biopharmaceutical company, focused on the development and commercialization of a new generation of biological drugs; ActoBiotics™ .

ActoBiotics™ are created using TopAct™ , ActoGeniX’s versatile and proprietary technology platform. They can be orally administered and target receptors and pathways in gastrointestinal tissues. This novel class of biopharmaceuticals has the potential to treat a broad range of severe diseases.

With several ActoBiotics™ in various stages of clinical and preclinical development, ActoGeniX’s initial focus is on areas with unmet need in gastrointestinal, immunological and metabolic diseases.

ActoGeniX’s lead product, AG013, is an ActoBiotic™ for the treatment of oral mucositis. In May 2009, the FDA approved ActoGeniX’s IND application, allowing the Company to initiate a phase 1B clinical trial with AG013 in cancer patients at risk of developing oral mucositis.

This clinical study has been recently finalized. AG013 was proven to be safe and well tolerated. Analysis of initial efficacy showed a 35% reduction of the percentage of days with ulcerative oral mucositis in the AG013-treated patients versus the placebo-treated patients. Furthermore, close to 30% of the patients treated with AG013 were full responders while all placebo-treated patients developed ulcerative oral mucositis.

 

 Video: What are ActoBiotics™ ?